Therapeutic area

Respiratory

Diseases of the lungs and airways, including chronic obstructive and restrictive conditions requiring long-term management.

Diseases

Asthma
$107.9B attributable cost
$45.6B drug spend
100 assets · 1 indication
Chronic Obstructive Pulmonary Disease
$48.0B attributable cost
$20.9B drug spend
42 assets · 1 indication

All assets in Respiratory

← all areas